Last reviewed · How we verify

NCT03704194: LiFE

Adapted Lifestyle-integrated Functional Exercise Program for Medically Underserved Older Adults

Completed NA Results posted Last updated 27 August 2025
What this trial tests

NA trial testing Adapted LiFE in Accidental Fall in 17 participants. Completed in 31 January 2019.

Timeline
1 August 2018
Primary endpoint
31 January 2019
31 January 2019

Quick facts

Lead sponsorWashington University School of Medicine
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeprevention
Enrollment17
Start date1 August 2018
Primary completion31 January 2019
Estimated completion31 January 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Washington University School of Medicine

Who can join

70 and older, any sex, with Accidental Fall. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

The Berg Balance Scale (BBS) Primary · Baseline and 12 weeks

The Berg Balance Scale (BBS) is a 14-item assessment of static and dynamic balance. Performance quality, time, and assistance required are rated on a scale of 0-4 based on pre-specified criteria. Total scores range from 0-56, with a score of 45 or below indicating high risk of falls.

Pre-test
GroupValue95% CI
Adapted LiFE40.63± 10.17
Attention Control35.25± 11.52
Post-test
GroupValue95% CI
Adapted LiFE38.38± 12.59
Attention Control35.88± 9.85
The Self-Reported Habit Index (SRHI) Secondary · Baseline and 12 weeks

The Self-Reported Habit Index (SRHI) is a 12-item assessment assesses habit exercise strength, frequency, relevance to self-identity, and automaticity. Items are self-rated with a seven-point Likert scale (1=strongly disagree, 7= strongly agree). Total score range from 12 to 84, where higher scores indicate stronger the habit is.

Pre-test
GroupValue95% CI
Adapted LiFE47.50± 21.67
Post-test
GroupValue95% CI
Adapted LiFE57.13± 19.26
The Activities-specific Balance Confidence Scale (ABC) Secondary · 12 weeks

The Activities-specific Balance Confidence Scale (ABC) is 16-item self-report measure in which participates rate their balance confidence for performing activities. Each item is rated on a 0-100 scale (0= no confidence, 100 = complete confidence). A final score is the average of all items ( range from 0 to 100).

Pre-test
GroupValue95% CI
Adapted LiFE60.77± 20.83
Attention Control52.46± 22.26
Post-test
GroupValue95% CI
Adapted LiFE60.63± 21.57
Attention Control60.7± 12.94
The Short Physical Performance Battery (SPPB) Secondary · Baseline and 12 weeks

The Short Physical Performance Battery-Balance Test (SPPB) assess balance and mobility with three subtests (score range: 0 to 4): standing balance, three-meter gait speed, and five repetitions of sit-to-stand motion. Total score are sums of subtest scores ranging from 0 (worst performance) to 12 (best performance).

Pre-test
GroupValue95% CI
Adapted LiFE6.38± 2.83
Attention Control5.25± 2.87
Post-test
GroupValue95% CI
Adapted LiFE5.25± 3.01
Attention Control5.38± 2.20
Center of Pressure (CoP) Path (cm) Secondary · Baseline and 12 weeks

Center of Pressure (Cop) is measured by a balance board system BtracKS. Participant stands on the balance board in 4 posture in three 30-second trials for each posture: hip-width stand (HS), hip-width stand with eyes closed (HSEC), narrow stand (NS), narrow stand with eyes closed (NSEC). Trajectory and mean velocity of CoP in each postures are calculated to represent static balance. Larger trajectory or velocity indicates lower static balance.

HS CoP Mean distance (cm) Pre-test
GroupValue95% CI
Adapted LiFE0.59± 0.13
Attention Control0.67± 0.32
HS CoP Mean distance (cm) Post-test
GroupValue95% CI
Adapted LiFE0.68± 0.16
Attention Control0.61± 0.19
HSEC CoP Mean distance (cm) Pre-test
GroupValue95% CI
Adapted LiFE0.59± 0.13
Attention Control0.69± 0.29
HSEC CoP Mean distance (cm) Post-test
GroupValue95% CI
Adapted LiFE0.68± 0.16
Attention Control0.72± 0.30
NS CoP Mean distance (cm) Pre-test
GroupValue95% CI
Adapted LiFE0.82± 0.09
Attention Control0.71± 0.17
NS CoP Mean distance (cm) Post-test
GroupValue95% CI
Adapted LiFE1.03± 0.43
Attention Control0.83± 0.32
NSEC CoP Mean distance (cm) Pre-test
GroupValue95% CI
Adapted LiFE1.13± 0.24
Attention Control0.99± 0.40
NSEC CoP Mean distance (cm) Post-test
GroupValue95% CI
Adapted LiFE1.39± 0.51
Attention Control1.12± 0.54
Center of Pressure (CoP) Velocity (cm/s) Secondary · Baseline and 12 weeks

Center of Pressure (Cop) mean velocity (cm/s) is measured by a balance board system BtracKS. Participant stands on the balance board in 4 posture in three 30-second trials for each posture: hip-width stand (HS), hip-width stand with eyes closed (HSEC), narrow stand (NS), narrow stand with eyes closed (NSEC). Larger velocity indicates a lower static balance.

HS CoP Mean velocity (cm/s) Pre-test
GroupValue95% CI
Adapted LiFE2.38± 1.05
Attention Control1.96± 0.55
HS CoP Mean velocity (cm/s) Post-tes
GroupValue95% CI
Adapted LiFE2.59± 1.52
Attention Control1.96± 0.74
HSEC CoP Mean velocity (cm/s) Pre-test
GroupValue95% CI
Adapted LiFE3.22± 2.03
Attention Control2.89± 1.11
HSEC CoP Mean velocity (cm/s) Post-test
GroupValue95% CI
Adapted LiFE4.01± 3.48
Attention Control3.02± 1.12
NS CoP Mean velocity (cm/s) Pre-test
GroupValue95% CI
Adapted LiFE3.18± 1.31
Attention Control2.93± 0.75
NS CoP Mean velocity (cm/s) Post-test
GroupValue95% CI
Adapted LiFE3.88± 2.20
Attention Control2.45± 1.05
NSEC CoP Mean velocity (cm/s) Pre-test
GroupValue95% CI
Adapted LiFE4.55± 1.88
Attention Control4.21± 2.30
NSEC CoP Mean velocity (cm/s) Post-test
GroupValue95% CI
Adapted LiFE5.05± 2.38
Attention Control4.30± 2.53
Lower Extremity Muscle Strength Secondary · Baseline and 12 weeks

Lower extremity muscle strength of hip and knee are measured by a dynamometer.

Hip flexors (right limb) Pre-test
GroupValue95% CI
Adapted LiFE18.11± 4.37
Attention Control19.86± 8.95
Hip flexors (right limb) Post-test
GroupValue95% CI
Adapted LiFE18.73± 12.55
Attention Control21.58± 15.75
Hip flexors (left limb) Pre-test
GroupValue95% CI
Adapted LiFE17.10± 4.94
Attention Control15.97± 7.67
Hip flexors (left limb) Post-test
GroupValue95% CI
Adapted LiFE19.79± 13.23
Attention Control19.25± 8.70
Knee flexors (right limb) Pre-test
GroupValue95% CI
Adapted LiFE23.83± 2.96
Attention Control24.15± 8.91
Knee flexors (right limb) Post-test
GroupValue95% CI
Adapted LiFE16.48± 9.51
Attention Control18.65± 8.22
Knee flexors (left limb) Pre-test
GroupValue95% CI
Adapted LiFE21.34± 4.47
Attention Control23.40± 6.66
Knee flexors (left limb) Post-test
GroupValue95% CI
Adapted LiFE15.01± 8.61
Attention Control19.1± 8.77
Recruitment and Retention Rate Are Documented by Therapist Logs Secondary · 16 weeks

The status of each potential participant we contacted is documented in an electronic therapist log. Treatment and control groups share the same recruitment rate since randomization took place after enrollment, and the two groups were not recruited separately. Recruitment rate will be measured by the percentage of participants successfully enrolled in the study. Retention rate is calculated by the number of participants completed divided by the number of participants enrolled. Retention rate is calculated by the number of participants completed divided by the number of participants enrolled.

Recruitment rate
GroupValue95% CI
Attention Control42.02
Adapted LiFE42.02
Retention rate
GroupValue95% CI
Attention Control100
Adapted LiFE100
Acceptance of the Intervention Programs is Measured by a Question. Secondary · 12 weeks

A question, "Are you satisfied with the program?," using a seven-point Likert scale from one (very unsatisfied) to seven (very satisfied) is used to represent acceptance. Score range: 1-7. Higher values indicate higher satisfaction.

GroupValue95% CI
Adapted LiFE6.88± 0.35
Adherence Rate is Documented by LiFE Activity Calendar Secondary · 12 weeks

Participants in the treatment group documents their exercise activities in the LiFE activity calendar. Adherence rate is defined as the average percentage of exercise activities achieved during the intervention period.

Session 1
GroupValue95% CI
Adapted LiFE79± 33
Session 2
GroupValue95% CI
Adapted LiFE87± 12
Session 3
GroupValue95% CI
Adapted LiFE73± 23
Session 4
GroupValue95% CI
Adapted LiFE76± 35
Session 5
GroupValue95% CI
Adapted LiFE73± 35
Session 6
GroupValue95% CI
Adapted LiFE74± 34
Session 7
GroupValue95% CI
Adapted LiFE51± 46
Fidelity is Documented by a Visit-by-visit Checklist Secondary · 12 weeks

Therapists in both treatment and control group complete a checklist after every visit. The checklist consist of pre-determined key activities. The number of delivered key activities divided by the number of planned key activities in all visits calculates a fidelity score.

GroupValue95% CI
Adapted LiFE100± 0
Attention Control100± 0
Adverse Events Secondary · 16 weeks

Safety of the program will be evaluated by the number of adverse events documented throughout the study duration.

GroupValue95% CI
Adapted LiFE0± 0
Attention Control0± 0

Sponsor's own description

This study will test the feasibility of a study design for the Adapted Lifestyle-integrated Functional Exercise (LiFE) program for medically underserved older adults and to explore factors related to implementation. A feasibility trial will be conducted with a total of 16 participants. The control group will receive flexibility exercise program as attention control.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Accidental Fall

Currently open trials in the same condition.

Other Washington University School of Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03704194.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing